{"id":164,"date":"2026-05-10T12:50:09","date_gmt":"2026-05-10T12:50:09","guid":{"rendered":"http:\/\/dali.imagidev.com\/?post_type=success_story&#038;p=164"},"modified":"2026-05-10T12:50:09","modified_gmt":"2026-05-10T12:50:09","slug":"advancing-retinal-drug-delivery-through-innovative-injection-technology","status":"publish","type":"success_story","link":"https:\/\/dali.imagidev.com\/index.php\/success_story\/advancing-retinal-drug-delivery-through-innovative-injection-technology\/","title":{"rendered":"Advancing Retinal Drug Delivery Through Innovative Injection Technology"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Background<\/strong><\/h2>\n\n\n\n<p>Everads Therapy (<a href=\"https:\/\/www.everads-therapy.com\/\">https:\/\/www.everads-therapy.com\/<\/a>) was founded as a spin-off startup company. The company was established within RAD Biomed, a premier biotech accelerator, and is built on core technologies licensed from the laboratory of Prof. Yigal Rotenstreich at Sheba Medical Center. DALIMED was chosen to join as a recognized leader in injectable drug delivery technologies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Challenge: Addressing a Critical Unmet Need<\/strong><\/h2>\n\n\n\n<p>Retinal diseases such as Age-related Macular Degeneration (AMD) require repeated intravitreal injections, which can be burdensome for patients and carry risks of side effects and complications. The medical community continues to seek solutions that improve drug delivery efficiency while reducing treatment frequency and patient discomfort.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>The Innovation<\/strong><\/h2>\n\n\n\n<p>The journey began when Sheba Medical Center approached DALIMED with a groundbreaking invention developed by Prof. Yigal Rotenstreich. The concept introduced a novel approach for delivering drugs to the back of the eye, targeting retinal diseases more effectively.<\/p>\n\n\n\n<p>This innovative method was designed to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enable superior distribution of therapeutic agents across the retina<\/li>\n\n\n\n<li>Target the posterior segment of the eye with higher precision<\/li>\n\n\n\n<li>Reduce the need for frequent intravitreal injections<\/li>\n\n\n\n<li>Minimize associated side effects and risks<\/li>\n<\/ul>\n\n\n\n<p><strong>Development Process<\/strong><br>Developing its first Ophthalmic injector, DALIMED focused on simplifying the injection procedure while maintaining high performance and safety standards.<\/p>\n\n\n\n<p>The development phase included:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Extensive preclinical testing across multiple models<\/li>\n\n\n\n<li>Iterative design improvements to optimize delivery efficiency<\/li>\n\n\n\n<li>Engineering refinements to enhance usability for clinicians<\/li>\n<\/ul>\n\n\n\n<p>Throughout this process, several new patents were successfully filed, strengthening the intellectual property portfolio and reinforcing the uniqueness of the solution.<\/p>\n\n\n\n<p><strong>Clinical Progress<\/strong><br>The product has successfully completed a Phase 1 clinical trial in humans, demonstrating a favorable safety profile and initial efficacy signals. Building on this success, the device is currently being evaluated in a Phase 2 clinical trial in combination with a therapeutic compound provided by one of Everads\u2019 partners.<\/p>\n\n\n\n<p>Starting the clinical trials was based on approved Investigational New Drug (IND) application after submitting a Master Access File (MAF) to the FDA.<\/p>\n\n\n\n<p><strong>Impact and Future Outlook<\/strong><br>This innovative drug delivery product has the potential to transform the treatment paradigm for retinal diseases by:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Reducing treatment burden on patients<\/li>\n\n\n\n<li>Improving clinical outcomes through better drug distribution<\/li>\n\n\n\n<li>Enhancing safety and patient compliance<\/li>\n<\/ul>\n\n\n\n<p>As clinical development progresses, Everads continues to collaborate with pharmaceutical partners to expand the application of its technology across multiple ophthalmic indications, aiming to set a new standard in retinal drug delivery.<\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/www.everads-therapy.com\/publications\n<\/div><\/figure>\n","protected":false},"featured_media":0,"template":"","class_list":["post-164","success_story","type-success_story","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dali.imagidev.com\/index.php\/wp-json\/wp\/v2\/success_story\/164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dali.imagidev.com\/index.php\/wp-json\/wp\/v2\/success_story"}],"about":[{"href":"https:\/\/dali.imagidev.com\/index.php\/wp-json\/wp\/v2\/types\/success_story"}],"version-history":[{"count":1,"href":"https:\/\/dali.imagidev.com\/index.php\/wp-json\/wp\/v2\/success_story\/164\/revisions"}],"predecessor-version":[{"id":165,"href":"https:\/\/dali.imagidev.com\/index.php\/wp-json\/wp\/v2\/success_story\/164\/revisions\/165"}],"wp:attachment":[{"href":"https:\/\/dali.imagidev.com\/index.php\/wp-json\/wp\/v2\/media?parent=164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}